In conclusion, our results suggest that FP NPs may exert a profound therapeutic effect on p53-mutant NSCLC and prevent NSCLC tumor recurrence and resistance to cisplatin therapy (Figs. 7–9). The gene discussed is TP53; the disease is non-small cell lung carcinoma.